TBIO Translate Bio Inc.

8.35
+0.34  (+4%)
Previous Close 8.01
Open 8.04
Price To Book 3.68
Market Cap 425,936,573
Shares 51,010,368
Volume 101,967
Short Ratio
Av. Daily Volume 336,704
Stock charts supplied by TradingView

NewsSee all news

  1. Translate Bio Announces Upcoming MRT5005 Presentations at the 33rd Annual North American Cystic Fibrosis Conference

    LEXINGTON, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Translate Bio (NASDAQ:TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat

  2. Translate Bio to Present at the 3rd Annual Chardan Genetic Medicines Conference

    LEXINGTON, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (NASDAQ:TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat

  3. Translate Bio Announces Pricing of Public Offering of Common Stock

    LEXINGTON, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (NASDAQ:TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat

  4. Translate Bio Announces Proposed Public Offering of Common Stock

    LEXINGTON, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (NASDAQ:TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat

  5. Translate Bio Announces Strategic Manufacturing Agreement with AMRI in Support of Messenger RNA (mRNA) Manufacturing

    --  Agreement provides Translate Bio with customized and dedicated manufacturing space for cGMP mRNA production for current and future programs -- LEXINGTON, Mass., Sept. 12, 2019 (GLOBE NEWSWIRE) -- Translate Bio

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 MAD data due 2020. Interim SAD data to be presented at NACFC November 1, 2019, 3:35pm CT.
MRT5005
Cystic fibrosis
Phase 1/2 IND placed on clinical hold - January 22, 2019. Development to be discontinued - noted September 9, 2019.
MRT5201
OTC deficiency

Latest News

  1. Translate Bio Announces Upcoming MRT5005 Presentations at the 33rd Annual North American Cystic Fibrosis Conference

    LEXINGTON, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Translate Bio (NASDAQ:TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat

  2. Translate Bio to Present at the 3rd Annual Chardan Genetic Medicines Conference

    LEXINGTON, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (NASDAQ:TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat

  3. Translate Bio Announces Pricing of Public Offering of Common Stock

    LEXINGTON, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (NASDAQ:TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat

  4. Translate Bio Announces Proposed Public Offering of Common Stock

    LEXINGTON, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (NASDAQ:TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat

  5. Translate Bio Announces Strategic Manufacturing Agreement with AMRI in Support of Messenger RNA (mRNA) Manufacturing

    --  Agreement provides Translate Bio with customized and dedicated manufacturing space for cGMP mRNA production for current and future programs -- LEXINGTON, Mass., Sept. 12, 2019 (GLOBE NEWSWIRE) -- Translate Bio

  6. Translate Bio Announces Pipeline Program Update

    - Prioritizing and expanding pulmonary disease programs based on early positive cystic fibrosis (CF) data for MRT5005, the first inhaled mRNA therapeutic –  - Discontinuing development of MRT5201, a liver-targeted